207 related articles for article (PubMed ID: 15028483)
1. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
Hwang DG
Surv Ophthalmol; 2004 Mar; 49 Suppl 2():S79-83. PubMed ID: 15028483
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
3. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Scoper SV
Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
[TBL] [Abstract][Full Text] [Related]
4. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Epstein SP; Bottone EJ; Asbell PA
Eye Contact Lens; 2006 Sep; 32(5):240-4. PubMed ID: 16974157
[TBL] [Abstract][Full Text] [Related]
6. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
Park SH; Lim JA; Choi JS; Kim KA; Joo CK
Cornea; 2009 Jan; 28(1):68-72. PubMed ID: 19092409
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.
Stroman DW; Dajcs JJ; Cupp GA; Schlech BA
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S16-31. PubMed ID: 16257308
[TBL] [Abstract][Full Text] [Related]
8. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
[TBL] [Abstract][Full Text] [Related]
9. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
Schlech BA; Alfonso E
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S7-15. PubMed ID: 16257313
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
Yamada M; Hatou S; Yoshida J
Eye Contact Lens; 2008 Mar; 34(2):109-12. PubMed ID: 18327047
[TBL] [Abstract][Full Text] [Related]
11. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
[TBL] [Abstract][Full Text] [Related]
12. [In vitro fluoroquinolone resistance in ocular bacterial isolates].
Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY
Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574
[TBL] [Abstract][Full Text] [Related]
13. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
Hedlin P; Blondeau JM
Eye Contact Lens; 2007 May; 33(3):161-4. PubMed ID: 17502752
[TBL] [Abstract][Full Text] [Related]
14. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
Kowalski RP; Yates KA; Romanowski EG; Karenchak LM; Mah FS; Gordon YJ
Ophthalmology; 2005 Nov; 112(11):1987. PubMed ID: 16183128
[TBL] [Abstract][Full Text] [Related]
15. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
[TBL] [Abstract][Full Text] [Related]
16. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
17. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Mather R; Karenchak LM; Romanowski EG; Kowalski RP
Am J Ophthalmol; 2002 Apr; 133(4):463-6. PubMed ID: 11931779
[TBL] [Abstract][Full Text] [Related]
18. Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument.
Jorgensen JH; Crawford SA; McElmeel LM; Whitney CG
J Clin Microbiol; 2004 Dec; 42(12):5928-30. PubMed ID: 15583344
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility comparisons of normal preoperative conjunctival bacteria to fluoroquinolones.
Hori Y; Nakazawa T; Maeda N; Sakamoto M; Yokokura S; Kubota A; Inoue T; Nishida K; Tano Y
J Cataract Refract Surg; 2009 Mar; 35(3):475-9. PubMed ID: 19251140
[TBL] [Abstract][Full Text] [Related]
20. [In vitro antibiotic susceptibility to fluoroquinolones].
Wong CA; Galvis V; Tello A; Villareal D; Rey JJ
Arch Soc Esp Oftalmol; 2012 Mar; 87(3):72-8. PubMed ID: 22423655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]